molecular
technolog
given
us
greater
insight
aetiolog
diseas
function
immun
system
mode
action
veterinari
pathogen
knowledg
gain
use
develop
new
vaccin
specif
reactiv
antigen
elicit
protect
immun
mediat
respons
humor
andor
cell
mediat
host
vaccin
burden
immun
system
initi
respons
nonessenti
antigen
howev
efficaci
vaccin
good
deliveri
technolog
rout
use
present
immun
system
vaccin
tradit
given
parenter
rout
given
natur
rout
either
oral
intranas
two
major
advantag
often
interrel
rapid
onset
immun
stimul
local
mucos
immun
new
technolog
make
impact
current
vaccin
develop
balanc
found
technolog
feasibl
provid
least
good
protect
immun
current
convent
vaccin
new
emerg
diseas
appear
global
new
opportun
aris
molecular
convent
technolog
appli
develop
deliveri
novel
vaccin
well
improv
vaccin
current
use
vaccinolog
advanc
consider
sinc
edward
jenner
first
immun
suscept
volunt
vaccinia
cowpox
viru
prevent
infect
smallpox
viru
le
fanu
although
vaccin
prepar
bear
resembl
crude
scab
homogen
year
ago
concept
vaccin
still
basi
vaccin
develop
today
ie
immun
attenu
kill
pathogen
elicit
protect
respons
homolog
close
relat
heterolog
pathogen
better
understand
immun
system
gain
last
year
deeper
knowledg
innat
acquir
immun
use
optim
target
vaccin
viral
intracellular
infect
like
elicit
th
cellular
immun
respons
subsequ
action
releas
cytokin
infg
tnf
well
document
howev
viral
bacteri
antigen
also
stimul
humor
immun
involv
th
cell
respons
antibodi
produc
plasma
cell
deriv
b
cell
recogn
free
antigen
viral
bacteri
parawwwelseviercomlocatevetm
veterinari
microbiolog
sitic
bodi
fluid
subsequ
bind
inactiv
virus
mani
ident
bind
site
antibodi
due
structur
symmetri
form
larg
aggreg
bound
immunoglobulin
taken
phagocyt
opsonis
destroy
levin
function
vaccin
aid
process
prime
anim
pathogen
invad
creat
memori
b
cell
stimul
cell
mediat
immun
last
year
safe
efficaci
vaccin
major
pathogen
dog
canin
distemp
canin
adenoviru
canin
parvoviru
leptospirosi
cat
felin
herpesviru
felin
calciviru
felin
panleucopenia
develop
compris
core
antigen
small
anim
vaccin
worldwid
countri
rabi
endem
signific
threat
vaccin
diseas
also
mandatori
howev
breakthrough
occur
field
occas
vaccin
anim
succumb
diseas
paper
briefli
discuss
caus
seem
lack
efficaci
vaccin
give
overview
vaccin
manufactur
develop
new
improv
prepar
use
current
molecular
technolog
avail
plethora
vaccin
wide
avail
veterinari
surgeon
inform
choic
made
vaccin
vaccin
regim
use
factor
preval
certain
type
diseas
particular
region
environ
may
influenc
use
vaccin
felv
cat
endem
area
vaccin
although
exampl
singl
cat
household
cat
housebound
core
vaccin
gener
throughout
europ
us
choic
made
product
claim
efficaci
earli
vaccin
presenc
matern
deriv
antibodi
mda
onset
immun
ooi
durat
immun
doi
sterilis
immun
countri
guidelin
issu
inform
bodi
recommend
vaccin
regim
use
inform
state
product
literatur
gaskel
et
al
diseas
canin
coronaviru
felin
bordetellosi
consid
seriou
enough
justifi
vaccin
although
vaccin
readili
avail
proceed
one
congress
state
new
felin
bordetella
vaccin
cure
search
diseas
wolf
howev
research
investig
catteri
breed
establish
multicat
household
may
disagre
statement
binn
et
al
indic
environ
influenc
vaccin
choic
last
year
felin
leukaemia
viru
felv
rigor
studi
molecular
level
order
discov
caus
diseas
knowledg
viru
led
prepar
variou
type
vaccin
includ
contain
whole
kill
adjuv
viru
subunit
envelop
glycoprotein
live
recombin
virus
express
envelop
protein
spark
latter
vaccin
shown
greater
efficaci
whole
whole
kill
viru
prepar
indic
advantag
select
correct
immunogen
immun
system
overwhelm
direct
respons
nonessenti
antigen
felin
immunodefici
viru
also
gain
high
profil
due
similar
hiv
first
fiv
vaccin
prepar
adjuv
inactiv
viral
clade
regist
claim
give
protect
clade
b
also
kusuhara
et
al
heterolog
broad
protect
interest
find
differ
clade
occur
contin
contin
even
within
us
state
state
fiv
vaccin
need
contain
clade
type
reli
synergist
cross
protect
would
reduc
antigen
load
cat
immun
system
dispel
fear
vaccin
contain
mani
unnecessari
constitu
effect
vaccin
canin
parvoviru
avail
sinc
type
viru
present
churchil
sinc
viru
evolv
europ
us
produc
type
vaccin
still
protect
new
strain
due
antibodi
respons
protein
greenwood
et
al
exampl
current
vaccin
protect
evolv
pathogen
demonstr
virus
chang
genet
level
current
vaccin
still
retain
efficaci
field
also
true
canin
distemp
canin
adenoviru
felin
herpesviru
felin
panleukopenia
strain
use
major
vaccin
sinc
first
develop
still
protect
field
strain
current
encount
felin
caliciviru
known
mani
biotyp
vaccin
manufactur
includ
two
strain
give
broader
protect
current
field
isol
anoth
vaccin
upgrad
mani
year
stabil
canin
leptospirosi
vaccin
l
canicola
l
icterohaemorrhagia
part
core
canin
vaccin
programm
strain
l
bratislava
l
pomona
l
grippotyphosa
frequent
caus
diseas
dog
vaccin
updat
includ
relev
serovar
also
short
overview
current
vaccin
show
mani
still
effect
first
introduc
signific
improv
would
trigger
lack
efficaci
new
field
isol
howev
owner
wish
socialis
anim
young
age
vaccin
need
confer
immun
quickli
presenc
matern
antibodi
major
justif
improv
current
core
vaccin
result
type
research
seen
ad
claim
today
major
vaccin
manufactur
due
recent
legisl
chang
pet
passport
scheme
control
movement
anim
countri
diseas
leishmaniasi
babesiosi
appear
countri
unit
kingdom
never
previous
encount
climat
chang
occur
worldwid
also
contribut
spread
vector
born
diseas
west
nile
fever
arthropod
vector
viru
found
far
north
uk
recent
serolog
studi
british
wild
bird
shown
evid
viru
half
bird
test
migrat
bird
mosquito
thought
respons
infect
speci
includ
crow
magpi
swallow
chicken
turkey
duck
buckley
et
al
although
viru
appear
caus
diseas
cat
dog
nevertheless
infect
vaccin
alreadi
develop
shown
experiment
protect
dog
cat
viraemia
karaca
et
al
case
zoonot
aspect
diseas
must
consid
even
though
diseas
clinic
appar
host
anim
hors
hand
particularli
prone
diseas
reach
southern
franc
infect
famou
hors
camargu
murgu
et
al
prevent
parasit
diseas
vaccin
proven
challeng
due
parasit
everchang
surfac
antigen
carbohydr
moieti
make
major
part
antigen
immun
system
respond
well
carbohydr
protein
respons
must
enhanc
adjuv
target
one
part
immun
system
vaccin
leishmaniasi
usual
consist
whole
freezedri
organ
l
infantum
vari
efficaci
new
adjuv
vaccin
triall
prepar
use
antigen
protein
excret
l
infantum
initi
result
promis
demonstr
immun
period
vaccin
dog
believ
due
th
activ
induc
infect
cell
produc
nitric
oxid
kill
parasit
clear
infect
cell
lemesr
et
al
new
vaccin
anoth
parasit
diseas
babesiosi
caus
intracellular
parasit
babesia
cani
claim
reduc
clinic
manifest
diseas
develop
contain
solubil
parasit
antigen
spa
adjuv
schetter
diseas
one
describ
increasingli
found
area
world
previous
diseasefre
caus
concern
health
endem
anim
also
zoonot
risk
human
popul
requir
avail
efficaci
vaccin
therefor
paramount
pathogen
spread
across
geograph
border
alarmingli
speci
speci
avian
influenza
headlin
news
due
report
human
becom
infect
die
follow
infect
strain
especi
asian
contin
wildfowl
carrier
viru
spread
consider
distanc
kuiken
et
al
experiment
infect
cat
viru
found
cat
excret
viru
develop
sever
diffus
alveolar
damag
transmit
viru
sentinel
cat
sign
anim
vari
virul
strain
may
caus
death
within
day
incub
period
day
kuiken
et
al
situat
close
monitor
societi
sensit
spread
diseas
small
anim
ever
sinc
sourc
sar
outbreak
associ
civet
tu
et
al
equin
influenza
viru
also
consid
speci
specif
first
time
believ
cross
speci
barrier
respons
death
eight
greyhound
florida
although
restrict
dog
kennel
jacksonvil
florida
still
import
signific
epidemiolog
event
genet
sequenc
analysi
shown
strain
viru
isol
dog
similar
strain
infect
hors
wisconsin
previou
year
specif
antibodi
viru
found
dog
impli
viru
replic
suffici
stimul
immun
respons
carey
brief
account
emerg
diseas
veterinari
import
highlight
need
awar
ever
chang
natur
pathogen
particular
virus
evolv
host
speci
overcom
vaccin
natur
antigen
drift
may
opportunist
find
new
host
new
speci
present
new
challeng
veterinari
medic
research
use
molecular
technolog
advanc
veterinari
vaccin
design
significantli
past
year
lead
develop
vector
subunit
marker
vaccin
applic
molecular
technolog
prevent
diseas
highlight
extens
wild
life
vaccin
programm
sylvat
fox
rabi
use
vaccinia
viru
recombin
express
rabi
glycoprotein
vrg
vaccin
result
mani
european
countri
rabi
free
pastoret
brochier
sinc
much
research
invest
produc
safe
efficaci
vaccin
use
technolog
econom
effici
way
safeti
vaccin
enhanc
revers
virul
longer
risk
excret
vaccin
viru
post
vaccin
elimin
vaccin
contain
subunit
fraction
pathogen
rather
whole
organ
also
less
immunestress
host
immun
system
direct
specif
antigen
spectrum
nonessenti
cell
structur
gene
respons
immunogen
epitop
pathogen
identifi
incorpor
bacteria
eg
e
coli
virus
eg
baculoviru
tissu
cultur
cell
eg
chines
hamster
ovari
express
protein
growth
medium
harvest
sometim
product
cell
protein
surfac
bound
antigen
may
concentr
purifi
adjuv
enhanc
immun
respons
typic
exampl
subunit
vaccin
avail
today
felin
leukaemia
vaccin
contain
felv
envelop
protein
jarrett
ganier
recombin
vaccin
produc
insert
gene
code
essenti
immunogen
pathogen
vector
usual
viral
incorpor
viral
genet
code
vector
inocul
anim
infect
target
cell
upon
replic
express
foreign
gene
protein
well
infect
cell
releas
protein
detect
immun
system
humor
andor
cell
mediat
immun
respons
initi
way
protect
neutralis
antibodi
rais
epitop
pathogen
without
presenc
whole
organ
choic
appropri
vector
often
made
use
one
found
natur
target
speci
exampl
although
canin
adenovirus
felin
herpesvirus
shown
effici
vector
inocul
respect
host
speci
may
viabl
due
circul
antibodi
present
vaccin
diseas
success
viral
vector
small
anim
found
poxvirusesmodifi
vaccinia
ankora
drexler
et
al
canarypox
paoletti
myxoma
mccabe
et
al
cat
dog
natur
infect
virus
dna
vaccin
could
describ
purest
vaccin
anim
inject
antigen
dna
encod
antigen
vaccin
inject
muscl
intraderm
needl
inject
optim
uptak
dna
encod
epitop
complet
antigen
integr
plasmid
along
promot
select
optim
transcript
yield
high
express
level
encod
protein
although
vaccin
elicit
cell
mediat
humor
immun
respons
target
speci
immun
respons
induc
dna
vaccin
may
lower
elicit
convent
vaccin
oyaski
hildegund
experiment
dna
vaccin
shown
protect
varieti
diseas
two
concern
product
suffici
quantiti
dna
make
vaccin
econom
transfect
effici
immun
respons
enhanc
significantli
use
gene
gun
electropor
increas
transfect
technolog
yet
advanc
stage
routin
use
especi
companion
anim
requir
userfriendli
procedur
gene
gun
avail
past
year
practic
disadvantag
nois
produc
gun
trigger
pressuris
ga
chamber
expel
dnacoat
gold
particl
epidermi
sudden
shock
could
well
make
anim
nervou
subsequ
visit
veterinari
surgeri
second
disadvantag
decid
inocul
anim
whose
bodi
cover
fur
signific
amount
work
undertaken
improv
efficaci
dna
deliveri
howev
first
two
dna
vaccin
veterinari
use
recent
grant
us
approv
anim
pharm
west
nile
viru
vaccin
hors
infecti
haematopoiet
necrosi
vaccin
farm
rear
atlant
salmon
landmark
dna
veterinari
vaccin
technolog
within
next
year
may
also
benefit
small
anim
vaccin
abil
manipul
dna
result
develop
marker
vaccin
allow
differenti
infect
vaccin
anim
field
henc
name
diva
vaccin
dna
vaccin
viru
manipul
delet
specif
gene
anim
produc
antibodi
code
protein
present
pathogen
differenti
diagnost
test
eg
elisa
develop
detect
particular
protein
absent
vaccin
serum
vaccin
anim
would
test
neg
infect
anim
would
test
posit
first
vaccin
use
way
aujeszki
diseas
vaccin
pig
glycoprotein
ge
thymidin
kinas
tk
gene
delet
vaccin
viru
pasick
present
vaccin
manufactur
requir
eu
direct
differenti
vaccin
field
pathogen
submit
registr
may
becom
realiti
sequenc
analysi
delet
gene
marker
fast
becom
routin
technolog
within
vaccin
r
laboratori
use
revers
genet
also
enabl
manipul
rna
virus
dna
recombin
vaccin
use
prophylact
biolog
diseas
research
ongo
use
therapeut
vaccin
especi
malign
canin
melanoma
bergman
et
al
contracept
vaccin
naz
antiallergi
vaccin
thoma
et
al
also
investig
especi
medic
field
area
interest
veterinari
profess
also
regardless
technolog
advanc
vaccin
develop
vaccin
good
rout
deliveri
abil
overcom
natur
barrier
matern
deriv
activ
circul
antibodi
host
anim
convent
mani
year
meant
vaccin
deliv
subcutan
sc
case
intramuscular
rout
diseas
parvoviru
distemp
system
antibodi
respons
correl
protect
vaccin
given
sc
im
rout
shown
produc
maintain
signific
protect
antibodi
level
mani
year
result
major
vaccin
compani
recommend
least
biannual
triannual
boost
certain
vaccin
compon
parvoviru
distemp
adenoviru
instead
annual
booster
prescrib
sinc
vaccin
regim
instig
howev
circul
matern
antibodi
young
anim
may
inhibit
take
certain
vaccin
given
young
age
instanc
canin
distemp
parvoviru
overcom
certain
degre
increas
titr
vaccin
viru
chalmer
baxendal
otherwis
second
even
third
vaccin
given
mda
level
decreas
suffici
ensur
vaccin
take
dna
recombin
vector
vaccin
one
solut
overcom
mda
young
anim
anoth
simpler
solut
give
vaccin
natur
rout
infect
take
place
becom
establish
particularli
relev
respiratori
pathogen
whose
main
tropism
cell
upper
respiratori
tract
oral
mucou
membran
kennel
cough
kc
vaccin
prime
exampl
organ
associ
kc
syndrom
name
bordetella
bronchiseptica
canin
parainfluenza
canin
adenoviru
includ
mono
bi
trival
vaccin
usual
given
prior
kennel
rapid
onset
immun
ooi
requir
usual
within
h
post
inocul
offer
durat
immun
doi
month
use
vaccin
dog
intermedi
year
immun
core
vaccin
cdv
cpv
doi
howev
mix
reaction
veterinari
profess
practic
intranasalor
vaccin
especi
larger
breed
dog
indic
compromis
reach
practic
effici
scientif
approach
control
releas
vaccin
import
develop
futur
give
potenti
singl
shot
vaccin
sustain
doi
polym
technolog
improv
possibl
coat
vaccin
microorgan
stabl
polymer
microspher
capabl
control
releas
success
tetanu
toxoid
allow
slow
releas
period
rang
day
month
jaganathan
et
al
modern
veterinari
surgeon
mani
choic
today
vaccin
use
includ
differ
construct
combin
rout
deliveri
deliveri
system
day
needl
syring
may
number
new
technolog
superced
tri
test
way
inform
choic
made
necessit
practition
kept
date
advanc
veterinari
vaccinolog
howev
prime
object
immunis
programm
regardless
technolog
protect
anim
quickli
possibl
maintain
immun
long
possibl
preval
diseas
vaccin
compani
address
issu
taken
ethic
view
vaccin
reduc
elimin
non
essenti
antigen
compon
achiev
doi
least
year
major
compon
veterinari
vaccin
includ
wide
rang
viral
bacteri
antigen
time
parasit
vaccin
develop
catch
vaccin
problemat
due
composit
increas
incid
exot
parasit
diseas
appear
new
region
imper
part
futur
vaccin
armouri
give
broad
protect
new
emerg
diseas
ideal
vaccin
one
shot
slow
releas
rapid
ooi
long
doi
given
presenc
mda
cheap
produc
creat
sterilis
immun
vaccin
may
still
achiev
obtain
deeper
understand
immun
system
technolog
manipul
